𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

✍ Scribed by Brian H. Kushner; Kim Kramer; Shakeel Modak; Li-Xuan Qin; Nai-Kong V. Cheung

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
137 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Single institution experience with high-
Single institution experience with high-dose cyclophosphamide, continuous infusion vincristine, escalating doses of VP-16-213, and total body irradiation with unpurged bone marrow rescue in children with neuroblastoma
✍ Kletzel, Morris ;Becton, David L. ;Berry, D. H. πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 378 KB

## Abstract Seven consecutive autologous bone marrow transplants were performed in children with neuroblastoma with very good partial remission (VGPR). A combination of cyclophosphamide, escalating doses of VP‐16‐213, continuous infusion vincristine, and total body irradiation followed by infusion

High dose chlorambucil versus Binet's mo
High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia : Results of an international multicenter randomized trial
✍ Branimir Jaksic; Maura Brugiatelli; Ivo Krc; Hajna Losonczi; Jerzy Holowiecki; A πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

vanced and/or progressive disease was defined by high Total Tumor Mass (TTM) score (ΓΊ9), and/or short doubling time (DT) (Γ΅12 months), and/or bone marrow for the International Society for Chemo-Immunotherapy, Vienna failure. The response to therapy was defined by reduction of the initial TTM score.

Cyclophosphamide plus dexamethasone is a
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

The addition of interferon or high dose
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486
✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera

Four versus six courses of a dose-escala
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma
✍ Nobert Schmitz; Marita Kloess; Marcel Reiser; Wolfgang E. Berdel; Bernd Metzner; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 252 KB